- Investing Ideas
- /
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
50
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
50 companies
Madrigal Pharmaceuticals
Market Cap: US$12.3b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$528.94
7D
11.2%
1Y
67.8%
Arcutis Biotherapeutics
Market Cap: US$2.9b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$23.45
7D
-3.8%
1Y
124.0%
Caris Life Sciences
Market Cap: US$7.1b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$24.77
7D
-15.2%
1Y
n/a
Mereo BioPharma Group
Market Cap: US$297.5m
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
MREO
US$1.84
7D
2.2%
1Y
-54.6%
Legend Biotech
Market Cap: US$5.9b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$31.18
7D
-2.6%
1Y
-20.8%
Achieve Life Sciences
Market Cap: US$253.9m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$4.72
7D
-4.3%
1Y
4.2%
ARS Pharmaceuticals
Market Cap: US$866.9m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$8.95
7D
-1.2%
1Y
-36.5%
Capricor Therapeutics
Market Cap: US$283.5m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$5.87
7D
-5.6%
1Y
-65.3%
RenovoRx
Market Cap: US$39.2m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.00
7D
-2.9%
1Y
-8.3%
Soleno Therapeutics
Market Cap: US$2.6b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$47.73
7D
1.8%
1Y
-14.3%
Lineage Cell Therapeutics
Market Cap: US$415.6m
A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.
LCTX
US$1.93
7D
6.0%
1Y
111.4%
Aldeyra Therapeutics
Market Cap: US$314.7m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$5.30
7D
7.5%
1Y
20.2%
OS Therapies
Market Cap: US$64.4m
A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
OSTX
US$1.92
7D
5.5%
1Y
-12.7%
Viridian Therapeutics
Market Cap: US$2.7b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$28.94
7D
18.5%
1Y
28.7%
AC Immune
Market Cap: US$335.4m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.28
7D
-4.4%
1Y
4.8%
Syndax Pharmaceuticals
Market Cap: US$1.5b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$16.79
7D
11.2%
1Y
1.0%
Longeveron
Market Cap: US$15.3m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$0.71
7D
-7.2%
1Y
-66.6%
Insmed
Market Cap: US$41.3b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$194.39
7D
4.0%
1Y
175.3%
Altimmune
Market Cap: US$446.2m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$4.23
7D
12.8%
1Y
-55.6%
TuHURA Biosciences
Market Cap: US$119.1m
A clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies.
HURA
US$2.23
7D
-10.8%
1Y
-54.9%
XOMA Royalty
Market Cap: US$416.9m
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
XOMA
US$33.62
7D
0.7%
1Y
13.2%
NewAmsterdam Pharma
Market Cap: US$4.3b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
NAMS
US$38.31
7D
3.4%
1Y
53.4%
uniQure
Market Cap: US$1.9b
Develops treatments for patients suffering from rare and other devastating diseases in the United States.
QURE
US$30.12
7D
15.6%
1Y
342.9%
Unicycive Therapeutics
Market Cap: US$84.6m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$5.14
7D
12.2%
1Y
7.5%
Marker Therapeutics
Market Cap: US$12.1m
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
MRKR
US$0.94
7D
2.9%
1Y
-74.1%
Ardelyx
Market Cap: US$1.5b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.04
7D
1.5%
1Y
34.2%
Anavex Life Sciences
Market Cap: US$588.4m
Operates as a biopharmaceutical company.
AVXL
US$6.90
7D
-5.6%
1Y
-22.4%
BioRestorative Therapies
Market Cap: US$12.2m
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX
US$1.38
7D
-5.5%
1Y
-10.4%
Rezolute
Market Cap: US$931.0m
A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
RZLT
US$10.00
7D
7.0%
1Y
77.3%
Rhythm Pharmaceuticals
Market Cap: US$6.7b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$97.92
7D
-1.6%
1Y
63.0%
Ionis Pharmaceuticals
Market Cap: US$11.7b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$72.67
7D
-2.7%
1Y
92.4%
Day One Biopharmaceuticals
Market Cap: US$1.1b
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$10.34
7D
13.1%
1Y
-30.4%
Creative Medical Technology Holdings
Market Cap: US$11.8m
A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
CELZ
US$2.99
7D
6.8%
1Y
11.2%
Sierra Oncology
Market Cap: US$1.3b
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs.
SRRA
US$54.99
7D
0.06%
1Y
179.4%
Zai Lab
Market Cap: US$2.4b
A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
ZLAB
US$21.88
7D
-11.8%
1Y
-26.9%
Annexon
Market Cap: US$355.3m
A clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
ANNX
US$2.84
7D
-5.6%
1Y
-56.6%